Premier Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Premier Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-34,095	Closed	-$879K	–	196
2021 Q1	$879K	Buy	+34,095	New	+$1.5M	0.16%	91
2020 Q4	–	Sell	-8,219	Closed	-$339K	–	178
2020 Q3	$339K	Buy	+8,219	New	+$355K	0.09%	105
2019 Q1	–	Sell	-17,870	Closed	-$293K	–	114
2018 Q4	$293K	Buy	+17,870	New	+$347K	0.08%	120

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Premier Asset Management's ACAD Position: Q2 2021 in Review

Premier Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 34,095 shares — an estimated $879K sold.

Premier Asset Management first reported a position in ACAD in Q4 2018 and held it in 3 quarters. The position peaked at $879K in Q1 2021. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Premier Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Premier Asset Management sold 34,095 Acadia Pharmaceuticals shares in Q2 2021, an estimated $879K.
Premier Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Premier Asset Management's Acadia Pharmaceuticals position peaked at $879K in Q1 2021.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Premier Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.